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Abstract
AIM: To undertake a randomised pilot study comparing 
biodegradable stents and endoscopic dilatation in 
patients with strictures.
 
METHODS: This British multi-site study recruited 
seventeen symptomatic adult patients with refractory 
strictures. Patients were randomised using a multicentre, 
blinded assessor design, comparing a biodegradable 
stent (BS) with endoscopic dilatation (ED). The primary 
endpoint was the average dysphagia score during 
the first 6 mo. Secondary endpoints included repeat 
endoscopic procedures, quality of life, and adverse 
events. Secondary analysis included follow-up to 12 
mo. Sensitivity analyses explored alternative estimation 
methods for dysphagia and multiple imputation of 
missing values. Nonparametric tests were used.
RESULTS: Although both groups improved, the 
average dysphagia scores for patients receiving 
stents were higher after 6 mo: BS-ED 1.17 (95%CI: 
0.63-1.78) P  = 0.029. The finding was robust under 
different estimation methods. Use of additional 
endoscopic procedures and quality of life (QALY) 
estimates were similar for BS and ED patients at 6 and 
12 mo. Concomitant use of gastrointestinal prescribed 
medication was greater in the stent group (BS 5.1, 
ED 2.0 prescriptions; P  < 0.001), as were related 
adverse events (BS 1.4, ED 0.0 events; P  = 0.024). 
Groups were comparable at baseline and findings were 
statistically significant but numbers were small due to 
under-recruitment. The oesophageal tract has somatic 
sensitivity and the process of the stent dissolving, 
possibly unevenly, might promote discomfort or reflux.
CONCLUSION: Stenting was associated with greater 
dysphagia, co-medication and adverse events. 
Rigorously conducted and adequately powered trials are 
needed before widespread adoption of this technology.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Benign oesophageal strictures are managed 
by endoscopic dilatation using balloons or bougies, 
often requiring costly repeat procedures. Biodegradable 
stents do not usually require removal and may reduce 
the need for repeated endoscopy. This pilot multi-
site randomized study demonstrates that stenting was 
associated with greater dysphagia, co-medication and 
adverse events. The oesophageal tract has somatic 
sensitivity and the process of the stent dissolving, 
possibly unevenly, might promote discomfort or reflux. 
Groups were comparable at baseline and findings 
are statistically significant but patient numbers were 
small. Rigorously conducted and adequately powered 
trials are needed before widespread adoption of this 
technology.
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INTRODUCTION
Benign oesophageal strictures (narrowing of  the 
oesophagus) present with dysphagia of  solid or liquid 
foods, which may result in malnutrition, aspiration, 
and weight loss. Strictures are conventionally treated by 
endoscopic dilatation using either a balloon (radially dilating 
the stricture) or a bougie (dilating the stricture by shearing 
longitudinal force). Balloon dilatation relieves dysphagia 
in about 80%-90% of  patients although associated with 
small risks of  bleeding and perforation[1] and, in around 
30%-40% of  patients, the stricture recurs needing repeated 
endoscopic dilatation[2]. Recurrence appears more common 
for complex strictures related to radiation therapy, 
corrosive injury or surgical anastomosis[3]. Repeat dilatation 
is preferred for refractory strictures when compared to 
surgery, which is associated with high morbidity rates as 
well as high risk for patients with comorbidities[4-6].
Balloon endoscopic dilatation involves inflating a 
polyethylene balloon within the stricture, for a minute 
or longer, followed by removal. Dilation stretches the 
narrowed oesophagus by radial distension, widening 
the lumen of  the oesophagus and relieving dysphagia. 
The biological dynamics of  the oesophagus response 
to short term stretching and the longer-term effects 
on the oesophageal wall are not well understood. 
Stretching is believed to disrupt the collagen and elastin 
fibres in the oesophageal wall, responsible for the 
fibrotic stricture, and open up the lumen. Most patients 
respond to the dilatation well and maintain luminal 
patency of  the oesophagus for a reasonable period of  
time. Some patients have recurrence of  their dysphagia 
as inflammation and ongoing fibrosis may cause the 
stricture to manifest again after several months.
Benign oesophageal strictures are caused by a number 
of  conditions: injury by acid reflux (peptic strictures); injury 
by ingestion of  acid or alkaline caustic agents (corrosive 
strictures); radiation induced inflammatory strictures; 
sequelae of  therapeutic endoscopic interventions for early 
oesophageal cancer and Barrett’s oesophagus (such as 
endoscopic mucosal resection or photodynamic therapy); 
post surgical anastomotic strictures[7]; and eosinophilic 
oesophagitis[8].
Self-expanding plastic or metal stents have been used 
to dilate benign recurrent oesophageal strictures, as a 
means of  reducing the need for repeated endoscopic 
balloon/bougie dilatation with mixed results and 
potential complications of  stent migration, hyperplastic 
tissue ingrowth or overgrowth (metal stents), oesophageal 
obstruction due to collapsed stent, thoracic pain and 
disappointing longer-term symptom relief[9-14]. These 
stents need to be removed after a period of  time and 
there can be complications both at insertion and removal. 
Mechanistically, a stent’s dilatory effect depends upon 
the strength and duration of  the radial distensile forces 
that act on the oesophageal wall over a period of  time, 
allowing the oesophagus to remodel around the stent. 
Biodegradable stents work to the same principle 
as removable metal/plastic stents without requiring 
endoscopic removal since the stent dissolves gradually 
in-situ, thus avoiding the need for it to be removed. 
The biodegradable stent under study (SX-ELLA BD 
Stent, ELLA-CS, s.r.o., Czech Republic®) is made from 
polydioxanone, a monocrystalline polymer that has 
been used in monofilament surgical suture materials, 
and has a 55% crystalline structure. It is degraded in 
living tissue by hydrolytic attack which breaks down 
the crystalline structure into smaller fragments of  low 
molecular weight products. Polydioxanone (PDX) has a 
greater resistance to hydrolytic attack when compared to 
other biodegradable polymers like polyglycolic acid or 
polylactic acid, both of  which have been used as stents, 
but with faster degradation times. The longer persistence 
of  the PDX stent is thought to allow adequate time for 
oesophageal remodelling to take place. Typically the stent 
maintains integrity and radial distensile force for 6-8 wk, 
and disintegrates in 11-12 wk following implantation.
A recent review identified 17 case series or reports 
of  PDX biodegradable stents reporting from 1 to 28 
patients, with follow-up from 2 to 18 mo and variable 
complication and clinical success[15]. The review identified 
a prospective comparison of  consecutive patients with 
refractory benign esophageal strictures receiving either 
self-expanding plastic stents, biodegradable stents or fully 
covered self-expanding metal stents (30 in each group)[9]. 
There were no significant differences in performance 
between stents although stricture length was significantly 
associated with higher recurrence of  symptoms. No 
randomized controlled trials comparing biodegradable 
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stents with other stents or with balloon dilatation were 
identified. Lack of  adequately robust evidence for 
effectiveness and cost-effectiveness formed the rationale 
of  this trial. 
MATERIALS AND METHODS
Study design
The study used a pilot multicentre randomised controlled 
trial design. Blinding of  clinicians and patients was not 
practicable; recording of  symptoms was performed by 
a single blinded observer at baseline, 3, 6 and 12 mo 
(research nurse). The trial protocol was registered at 
inception (ISRTCN 05817794), and a favourable opinion 
from an NHS research ethics committee and NHS local 
research management and governance approvals were 
obtained prior to starting.
Study population
Between March 2011 and June 2013, adult symptomatic 
adult patients diagnosed with a new or existing benign 
oesophageal stricture were recruited prospectively from 
participating NHS hospital sites. All participants provided 
informed consent and were then screened to confirm 
their eligibility before randomisation. 
Inclusion criteria included: written informed consent; 
confirmed diagnosis of  benign oesophageal stricture; 
aged 18-85 years; at least one previous oesophageal 
dilatation. Exclusion criteria included: patients with 
high strictures (within 2 cm of  the upper oesophageal 
sphincter); patients pregnant or not taking appropriate 
contraception; receiving anti-coagulants; diagnosis of  
oesophageal cancer (previous or current) or terminal 
disease; any medical illness inhibiting participation in the 
view of  the recruiting clinician; and patients who lack 
capacity. Patients were allowed to withdraw from the 
study at any time.
Randomisation and treatments
Randomisation was web-based, stratified by hospital 
site with a block size of  four, allocating patients in a 
1:1 ratio to biodegradable oesophageal stent (BS) or 
standard endoscopic balloon dilatation (ED). To ensure 
concealment of  allocation the recruiting clinician 
provided patient details before allocation was disclosed. 
Procedures 
The biodegradable stent used was CE-marked SX-
ELLA Stent Esophageal Degradeable BD, placed by a 
Consultant Gastroenterologist or Consultant Surgeon 
experienced in the procedure and in accordance with 
the manufacturer’s instructions. Logistical assistance was 
available from the distributor of  the stent in the United 
Kingdom (United Kingdom Medical, Sheffield, United 
Kingdom) if  required. Stent size was determined by the 
length of  the stricture, and allowing a minimum 1 cm 
overlap onto the normal oesophageal mucosa on either 
side. Two overlapping stents could be used if  the stricture 
exceeded the longest stent size available. The stent was 
placed endoscopically with radiological fluoroscopic 
assistance and, where possible, internal markers with 
contrast injection and the stent radio-opaque markers 
were used to determine the accurate positioning of  the 
stent.
Endoscopic balloon dilatation followed standard 
clinical practice. A standard CRE® dilatation balloon 
(Boston Scientific Corp Inc), either wire guided or non-
wire guided, was used as needed. Fluoroscopy was 
recommended for tight and complex strictures, but might 
not be required for simple strictures. A luminal diameter 
of  15 mm was considered successful optimal dilatation: 
multiple dilatation sessions could be used to achieve this 
with a frequency of  one dilatation every 2-3 wk, with a 
goal of  15 mm or the maximal achievable diameter if  
less. Follow up for all patients commenced after the first 
complete endoscopic dilatation procedure. 
Where a procedure used fluoroscopy, the maximum 
fluoroscopy screening time (exposure time) was 5 minutes 
for oesophageal stenting (maximum 1 session) or 2.5 min 
per session for balloon dilatation (with a maximum of  2 
sessions anticipated). Exposure equated to a few months 
natural background radiation. The Health Protection 
Agency terms this as a very low level of  risk to patients.
Endpoints
The primary outcome was the average dysphagia score 
during the first 6 mo, where dysphagia was patient-
assessed on a five-point scale. Secondary analysis of  the 
primary endpoint included average dysphagia scores to 
12 mo and area-under curve (AUC) estimates. Sensitivity 
analyses explored the robustness of  findings using 
repeated measures ANOVA and multiple imputation of  
missing values, using 6 and 12 mo follow-up data.
Secondary endpoints were assessed at the same visits 
as the primary outcome but were performed by a non-
blinded observer. Secondary endpoints assessed were: the 
number of  repeat endoscopic procedures (therapeutic 
and diagnostic); adverse events (including hospital 
admissions); quality of  life assessed physically using 
the surrogate markers of  weight; generic quality of  life 
assessment (EuroQol EQ-5D); and resource items.
Adverse events were recorded and categorised for 
severity (mild, moderate of  severe) and relatedness (not, 
unlikely, possibly, probably, definitely) to intervention as 
well as for expectedness and resolution. 
Statistical methods
Although not a formal requirement of  a pilot study, a 
power calculation was performed at the design stage. The 
dysphagia score uses a five-point severity scale; when 
averaged over a number of  points in time it behaves 
approximately as a continuous measure. A published case 
series reported typical standard deviations for dysphagia 
scores of  0.7-0.8[11]. Assuming an average (clinically 
worthwhile) difference of  1 point (SD 1.0) when 
comparing the new intervention to standard care, with α 
= 0.05 and power 90%, it was estimated 23 patients were 
required in each group. Allowing for a dropout rate of  
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At baseline, BS and ED were similar in demographic 
and disease history measures (Table 1), and comorbidities 
(Table 2). Procedural balloon and stent parameters at 
intervention were within normal expectations (Table 1).
Dysphagia scores
Although both groups improved, average dysphagia score 
for patients receiving stents remained significantly higher 
after 6 mo: BS-ED 1.17 (95%CI: 0.63-1.78) p = 0.029. 
(Table 3, Figure 2) Estimation of  dysphagia by AUC 
method was similar (noting the 0.5 weighting for a 6 mo 
average). Analysis at 12 mo provided qualitatively similar 
findings but with borderline statistical significance.
Sensitivity analyses explored the impact upon 
dysphagia using repeated measures ANCOVA, adjusting 
for baseline dysphagia and hospital site. Additionally, 
missing values were imputed (one value at 6 mo and four 
values at 12 mo) and mean dysphagia scores and repeated 
measure estimates were produced for the imputation 
dataset. Qualitatively, findings were similar for a range 
of  sensitivity analyses of  the primary endpoint with a 
statistically significant or borderline significant average 
increase in dysphagia score of  about 1 point for patients 
receiving a stent (Table 4).
Quality of life and recurrence
Quality of  life (QALY) estimates were similar for BS 
and ED patients regardless of  estimation by EQ-5D or 
EQ-VAS, or 6 mo or 12 mo follow up. Similarly, there 
10%, the study planned to recruit 50 patients. 
Statistical significance was assessed using bootstrapping 
with 10000 replications for continuous measures and 
Fisher’s exact test for count data. Secondary significance 
testing of  continuous measures was conducted by Mann-
Whitney U (MWU) non-parametric testing. Dysphagia 
area-under curve (AUC) and QALY scores were estimated 
using the trapezoidal rule. Consequently 6 mo endpoints 
were weighted by 0.5 (years) and 12 mo endpoints by one 
(year). 
Multiple imputation of  missing values was performed 
using age at randomisation, gender, weight, height, 
dysphagia at 0 and 3 mo as predictor variables and 
dysphagia at 6 and 12 mo as imputed and predictor 
variables with 10 imputations.
All analyses followed intention-to-treat principles and 
were conducted using SPSS (Statistical Package for the 
Social Sciences) 21 (IBM Corporation, New York, United 
States).
RESULTS
Subject baseline characteristics
When the study had recruited 17 patients (10 BS and 7 
ED), it was agreed with the sponsor to close the study 
due to low recruitment. One patient from each group 
was subsequently withdrawn before treatment due to 
in-eligibility (BS: mental incapacity; ED prior cancer), 
leaving 9 BS and 6 ED patients for analysis (see Figure 1). 
18202 December 28, 2014|Volume 20|Issue 48|WJG|www.wjgnet.com
Assessed for eligibility (n  = 68)
Excluded (n  = 51)
Not meeting inclusion criteria (n  = 31)
Declined to participate (n  = 3)
Other reasons (n  = 4)
Randomized (n  = 17)
Biodegradable stent, BS (n  = 10)
   Received allocation (n  = 9)
   Did not received) allocation (n  = 1) 
   1: Ineligible, mental incapacity
Endoscopic balloon dilation, ED (n  = 7)
   Received allocation (n  = 6)
   Did not received) allocation (n  = 1 ) 
   1: Ineligible, previous cancer
Lost to follow-up 3-6 mo (n  = 0) Lost to follow-up 3-6 mo (n  = 1) 
1: Loss of mental capacity
Analysed at 6 mo (n  = 9) Analysed at 6 mo (n  = 5)
Lost to follow-up at 6-12 mo (n  = 1) 
1: Reason unknown
Lost to follow-up 6-12 mo (n  = 1)
1: Study terminated
Analysed at 12 mo (n  = 8) Analysed at 12 mo (n  = 4)
Figure 1  Consort flow diagram.
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Table 2  Baseline comorbidities  n  (%)
were no differences in the number of  post-intervention 
additional endoscopic procedures. However a consistent, 
non-significant, pattern of  greater intervention was noted 
in the BS group (Table 3).
Tolerability of treatment
Adverse events were more common in patients receiving 
a stent: in total (mean/patient: BS 4.9, ED 1.0; p = 0.01); 
assessed as related to intervention (possibly, probably, 
definitely) (mean/patient: BS 1.4, ED 0; p = 0.024); and 
assessed as severe (mean/patient: BS 1.8, ED 0; p = 0.026) 
(MWU). Numbers of  patients reporting adverse events 
by type are tabulated (Table 5).
Concomitant use of  gastrointestinal prescribed 
medication was greater in the stent group (mean/patient: 
BS 5.1, ED 2.0 prescriptions; p < 0.001) (MWU). 
Numbers of  patients using concomitant medications by 
symptom are tabulated (Table 6).
DISCUSSION
This pilot study is the first randomised controlled trial 
comparing biodegradable stent and balloon dilatation for 
benign oesophageal stricture. Although the trial findings 
are diminished by under-recruitment, the randomised 
comparison remains valid and does not support the use 
of  biodegradable stents. Stenting was associated with 
greater dysphagia, co-medication and adverse events. This 
may have occurred in part because of  chance atypical 
low dysphagia follow-up scores in the balloon dilatation 
group, causing biodegradable stents to perform poorly 
by comparison. However, dysphagia and other baseline 
characteristics were similar between groups at baseline, 
validating the comparison. 
This study aimed to recruit 50 patients at 6 centres 
across the North East of  England. From the outset 
there were issues with under-recruitment; a potential 
explanation might be the steady increase in the use 
of  proton pump inhibitors in primary care since the 
publication in England of  the NICE Guidelines for 
management of  Dyspepsia in Adults[16], thought to have 
contributed to a reduction in oesophageal strictures[17,18]. 
Recruitment was closed after 17 patients were recruited 
with no prospect of  reaching the target within a 
reasonable time-scale. Subsequently the primary endpoint 
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Table 1  Baseline characteristics
  Endoscopic balloon dilatation Biodegradable Stent Mean difference p  value1
mean ± SD Min Max n mean ± SD Min Max n
Age (yr) 63.8 ± 9.1   54   74 6   62.7 ± 12.5   40   78 9 -1.1 1.000
Age at diagnosis (yr)   61.9 ± 10.5   49   74 6   59.6 ± 13.9   36   77 9 -2.3 0.955
Gender male:female [5:1] [8:1] 1.000
Weight (kg)   61.0 ± 10.0   47   71 6   71.7 ± 29.5   45 141 9 10.7 0.864
Height (cm) 168 ± 14 143 181 6 170 ± 10 156 188 9   2.0 1.000
Smoking (never:previously:currently) (1:2:3) (4:2:3) 0.660
Time since quitting smoking (yr)   4.3 ± 5.7       0.3     8.3 2   1.8 ± 1.5       0.7       2.8 2 -2.5 1.000
n cigarettes/d (if current) 18.3 ± 2.9 15 20 3 18.3 ± 2.9 15   20 3 0.0 1.000
Current drinker (no:yes) (3:3) (4:5) 1.000
Alcohol units/w (if current)   22.3 ± 17.2 10 42 3   15.8 ± 11.0   1   29 5 -6.5 0.786
Number of dilatations (ever)   3.2 ± 2.3   1   6 6   6.2 ± 5.1   1   16 9   3.0 0.224
Number of dilatations (in last 12 m)   1.2 ± 0.8   0   2 6   1.9 ± 1.8   0     5 9   0.7 0.607
Stricture length (cm)2   4.0 ± 1.9   2    6 5   3.5 ± 1.3   2     5 8 -0.5 0.524
Luminal diameter (mm)2 12.3 ± 4.9   9 18 3   23.2 ± 31.8   6   80 5 10.9 1.000
Extent of stricture (from)2 31.0 ± 3.7 25 36 6 34.6 ± 2.5 30   38 8   3.6 0.081
Extent of stricture (to)2 35.8 ± 2.9 32 40 5 38.0 ± 1.9 34   40 8   2.2 0.171
Dysphagia score (baseline)   1.83 ± 0.98   1   3 6   2.00 ± 1.22   0     4 9 0.17 0.776
EQ5D score (baseline)   0.69 ± 0.31       0.26   1 6   0.69 ± 0.24        0.36     1 9 0.00 0.955
EQVAS score (baseline)   73 ± 21 35 95 6   57 ± 22 30   95 9 -16 0.145
Intervention balloon dilatation (mm) 14.5 ± 1.2 12 15 6
Intervention stent length (mm)   96.1 ± 31.5 60 135 9
Intervention fluoroscopy (no:yes) (4:2)    (0:9)     0.011
1Continuous measures: independent samples Mann-Whitney U Test (exact significance); count data: Fisher’s exact test; 2At endoscopy prior to intervention.
Endoscopic balloon 
dilatation (n  = 6)
Biodegradable 
stent (n  = 9)
p  
value1
Alcohol dependence   3 (50)   5 (56) 1.000
Alcohol overdose 0 (0)   1 (11) 1.000
Appendicitis   1 (17)   1 (11) 1.000
Barrett's oesophagus 0 (0)   1 (11) 1.000
Biliary colic 0 (0)   1 (11) 1.000
Diarrhoea 0 (0)   1 (11) 1.000
Diverticular disease   2 (33)   1 (11) 0.525
Duodenitis 0 (0)   1 (11) 1.000
Reflux disease/oesophagitis   4 (67)   3 (33) 0.315
Haematemesis   1 (17) 0 (0) 0.400
Helicobacter pylori   1 (17) 0 (0) 0.400
Hiatus hernia   2 (33)   3 (33) 1.000
Inguinal hernia 0 (0)   1 (11) 1.000
Ischaemic sigmoid colon 
stricture
0 (0)   1 (11) 1.000
Oesophageal perforation 0 (0)   1 (11) 1.000
Perforated duodenal ulcer   1 (17) 0 (0) 0.400
Reversal of ileostomy 0 (0)   1 (11) 1.000
Wernicke's Encephalopathy 0 (0)   1 (11) 1.000
1Count data: Fisher’s exact test.
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of  average dysphagia score over 12 mo was altered to 6 
mo to increase the number of  completed scores. Due to 
low recruitment, the trial was kept open to recruitment 
for longer than originally anticipated. Imputation of  
missing values was used to support the primary analysis, 
which used complete-patient data. The change of  time-
frame did not impact qualitatively on the findings.
It might appear counterintuitive that an intervention 
to restore oesophageal topology might fail to improve 
dysphagia when compared to (transient) balloon 
dilatation. However the oesophageal tract has somatic 
sensitivity and the process of  the stent dissolving, 
possibly unevenly, might promote discomfort or reflux. 
Biodegradable stents lose their radial force over time 
as they degrade and may cause stent-induced mucosal 
or parenchymal injury. Findings from this pilot trial 
are qualitatively consistent with positive case reports 
and series reported in the literature, since stent group 
symptom scores similarly improved over time. Given 
the possibility of  regression to mean (patients treated 
at an acute point tending to improve over time), the 
findings underline the need for a rigorously conducted 
and adequately powered trial before widespread 
adoption of  this technology. Validated measures of  
patient experience should be incorporated. Findings also 
highlight the need to demonstrate organizational, clinical 
and patient support in achieving recruitment. Given the 
cost of  biodegradable stents (the stent cost excluding 
placement was £900/patient within the study), cost-
effectiveness analysis should be included within such a 
trial.
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Table 3  Outcomes
Endoscopic balloon dilatation Biodegradable stent Mean 
difference
95%CI p  value1 p  value2
mean ± SD Min Max n mean ± SD Min Max n
Primary endpoint
Dysphagia Score (Average 3 and 6 m) 0.00 ± 0.00 0.00 0.00 5 1.17 ± 0.90 0.00 3.00 9  1.17  0.63-1.78 0.029 0.004
Secondary endpoints
Dysphagia Score (AUC 0-6 m) 0.25 ± 0.13 0.13 0.38 5 0.71 ± 0.46 0.25 1.50 9  0.46  0.16-0.78 0.045 0.042
Dysphagia Score (Average 3, 6 and 12 m) 0.00 ± 0.00 0.00 0.00 4 1.21 ± 1.08 0.00 3.33 8  1.21  0.56-2.00 0.052 0.016
Dysphagia Score (AUC 0-12 m) 0.22 ± 0.12 0.13 0.38 4 1.28 ± 1.01 0.25 3.25 8  1.06  0.43-1.81 0.066 0.008
QALY (EQ5D 0-6 m) 0.34 ± 0.16 0.18 0.50 5 0.35 ± 0.10 0.22 0.48 9  0.00 -0.15-0.15 0.995 1.000
QALY (EQ5D 0-12 m) 0.64 ± 0.42 0.14 1.00 4 0.66 ± 0.23 0.38 0.98 7  0.01 -0.38-0.47 0.949 0.927
QALY (EQVAS 0-6 m) 0.36 ± 0.09 0.24 0.46 5 0.32 ± 0.09 0.22 0.45 9 -0.04 -0.14-0.05 0.385 0.364
QALY (EQVAS 0-12 m) 0.73 ± 0.20 0.49 0.92 4 0.67 ± 0.21 0.42 0.94 7 -0.07 -0.29-0.18 0.602 0.648
Number of additional procedures (0-6 m) 0.80 ± 1.10 0.00 2.00 5 3.22 ± 2.91 0.00 8.00 9  2.42  0.127
Number of endoscopic procedures (0-6 m) 0.00 ± 0.00 0.00 0.00 5 0.33 ± 0.71 0.00 2.00 9  0.33  0.505
Number of balloon procedures (0-6 m) 0.40 ± 0.55 0.00 1.00 5 1.22 ± 1.39 0.00 4.00 9  0.82  0.275
Number of endoscopies (0-6 m) 0.40 ± 0.55 0.00 1.00 5 1.67 ± 1.50 0.00 4.00 9  1.27  0.107
Number of additional procedures (0-12 m) 1.20 ± 0.84 0.00 2.00 5 4.13 ± 3.87 0.00 10.0 8  2.93  0.165
Number of endoscopic procedures (0-12 m) 0.00 ± 0.00 0.00 0.00 5 0.63 ± 1.06 0.00 3.00 8  0.63  0.417
Number of balloon procedures (0-12 m) 0.40 ± 0.55 0.00 1.00 5 1.38 ± 1.77 0.00 5.00 8  0.98  0.385
Number of endoscopies (0-12 m) 0.80 ± 0.45 0.00 1.00 5 2.13 ± 1.89 0.00 5.00 8  1.33  0.203
1Continuous measures: bootstrap estimation, 10000 replications; count data: Fisher’s exact test for trend; 2Continuous measures: independent samples 
Mann-Whitney U Test (exact significance).
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Figure 2  Dysphagia scores. 
Table 4  Sensitivity analyses
Mean 
difference
95%CI p  
value1
p 
value2
Repeated measures ANOVA
Dysphagia score (3, 6 m) 1.17 (0.21-2.13) 0.022
Dysphagia score (3, 6, 12 m) 1.10 (-0.11-2.31) 0.070
Repeated measures ANOVA 
(imputed)
Dysphagia score (3, 6 m) 1.13 (-0.05-2.32) 0.058
Dysphagia score (3, 6, 12 m) 1.01 (-0.30-2.32) 0.113
Dysphagia score (imputed)
Dysphagia score (Average 3 
and 6 m)
0.94 (0.18-1.70) 0.015 0.021
Dysphagia score (Average 3, 6 
and 12 m)
0.93 (0.06-1.79) 0.036 0.025
Dysphagia score (AUC 0-6 m) 0.38 (0.03-0.73) 0.032 0.075
Dysphagia score (AUC 0-12 m) 0.83 (0.07-1.58) 0.033 0.024
1Imputed values (pooled imputed value of z scores); 2Independent 
samples Mann-Whitney U Test (pooled asymptotic value).
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Benign oesophageal strictures are managed by endoscopic dilatation using 
balloons or bougies, often requiring repeat procedures with their associated 
risks and costs and discomfort to patients. Biodegradable stents do not usually 
require removal and may reduce the need for repeated endoscopy.
Research frontiers
No randomized controlled trials comparing biodegradable stents with other 
stents or with balloon dilatation have been identified. Lack of adequately robust 
evidence for effectiveness and cost-effectiveness formed the rationale of this 
trial.
Innovations and breakthroughs
This pilot multi-site randomized study demonstrated that stenting was 
associated with greater dysphagia, co-medication and adverse events. Groups 
were comparable at baseline and findings are statistically significant but patient 
numbers are small. 
Applications
The oesophageal tract has somatic sensitivity and the process of the stent 
dissolving, possibly unevenly, might promote discomfort or reflux. Rigorously 
conducted and adequately powered trials are needed before widespread 
adoption of this technology.
Terminology
Benign oesophageal stricture: Narrowing of the oesophagus is often caused 
by injury or radiation which leads to difficulty swallowing; Biodegradable stent: 
A hollow structure placed into the oesophagus which gradually dissolves; 
Endoscopic dilatation: A procedure conducted under anaesthesia to stretch the 
oesophagus, usually by means of an endoscopic balloon. 
Peer review
This is a good research idea as it is an important clinical entity. This is a nice 
pilot study that compares biodegradable stents and balloon dilatation. It is 
a well-designed study that unfortunately was not completed due to lack of 
included patients.
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